Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study-Reference-Cited by-同舟云学术

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Published:2019-04 Issue:4 Volume:20 Page:518-530
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Meric-Bernstam Funda,Hurwitz Herbert,Raghav Kanwal Pratap Singh,McWilliams Robert R,Fakih Marwan,VanderWalde Ari,Swanton Charles,Kurzrock Razelle,Burris Howard,Sweeney Christopher,Bose Ron,Spigel David R,Beattie Mary S,Blotner Steven,Stone Alyssa,Schulze Katja,Cuchelkar Vaikunth,Hainsworth John

Funder

Center for Clinical and Translational Sciences

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer;Zhao;Oncotarget,2017

2. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer;Raghav;J Clin Oncol,2016

3. HER2/neu testing in primary colorectal carcinoma;Ingold Heppner;Br J Cancer,2014

4. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression;Seo;PLoS One,2014

5. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3;Ross;Cancer,2018

Cited by 414 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

3. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

4. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation;npj Precision Oncology;2024-09-09

5. Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer;Case Reports in Oncology;2024-09-09